close
Enquiry IconContact Us
Logo

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Anal cancer is an uncommon type of cancer, which begins around or just inside the anal opening. Anal cancer can be classified into different types such as carcinoma in-situ, squamous cell carcinoma, melanoma, adenocarcinoma, and basal cell carcinoma. Carcinoma in-situ refers to stage zero anal cancer wherein the cancerous cells remain only at the site of its origin and does not spread to other parts of the body. Anal canal is lined by flat squamous cells and when these cells turn cancerous it gives rise to squamous cell carcinoma, which is the most common type of anal cancer. Melanoma begins in the cells responsible for production of color of skin or anal lining. Adenocarcinoma begins in the mucous production glands present under the anal lining. Basal cell carcinoma occurs in the perianal skin (around the anus). Some of the common symptoms that appear if one has anal cancer include swelling of anus, bleeding in the anus, and discharge from the anus, irregular bowel movements, and others. Anal cancer can be treated using chemotherapy, surgery, immunotherapy, and radiation therapy.

The global anal cancer market is estimated to be valued at US$ 810.4 million in 2021 and is expected to exhibit a CAGR of 6.3% over the forecast period (2021-2028).

Figure 1. Global Anal Cancer Market Share (%), By Region, 2021

Anal Cancer  | Coherent Market Insights

The increasing incidence of anal cancer and sexually transmitted diseases is expected to drive the growth of the global anal cancer market over the forecast period.

For instance, according to data published by the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program, U.S, it is estimated that the rate of new cases of anal cancer has increased from 1.7 per 100,000 persons in 2008 to 1.8 per 100,000 persons in 2018 and is expected to increase following the same trend in near future.

Figure 2. Global Anal Cancer Market Share (%), By Treatment Type, 2021

Anal Cancer  | Coherent Market Insights

The increasing research and development activities for the development of novel therapeutics for the treatment of anal cancer is expected to drive the market growth over the forecast period.

Key players operating in the market are focusing on research and development activities for treatment of anal cancer, which is expected to drive growth of the global anal cancer market over the forecast period.

For instance, in October 2016, Dana-Farber Cancer Institute, Massachusetts and Merck Sharp & Dohme Corp., a U.S. based pharmaceutical company initiated a phase II clinical trial study for assessing the potential use of Pembrolizumab, a monoclonal antibody drug manufactured by Merck Sharp & Dohme Corp. for treatment of advanced anal cancer. This phase II clinical study is expected to be completed by March 2023.

request-sample

Anal Cancer Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$  810.4 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 6.3% 2028 Value Projection: US$ 1,242.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Fluorouracil, Cisplatin, Carboplatin, Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
  • By Cancer Type: Carcinoma In-situ, Squamous Cell Carcinoma, Melanoma, Adenocarcinoma, Basal Cell Carcinoma
  • By Treatment Type: Chemotherapy, Surgery, Radiation Therapy, Immunotherapy
  • By Distribution Channel: Hospitals & Clinics, Research & Academic Institutes, Long-term Care Centers, Pharmacies
Companies covered: Advaxis, Inc., ORYX GmbH and Co. KG, Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Onconova Therapeutics, BioMimetix JV, LLC, Bayer AG, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., Atara Biotherapeutics Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Sanofi, and Johnson & Johnson Private Limited
Growth Drivers:
  • Increasing prevalence of sexually transmitted diseases and anal cancer
  • Growing research and development activities by market players for anal cancer treatment
Restraints & Challenges:
  • Side effects of chemotherapy drugs used for anal cancer treatment

Global Anal Cancer Market – Impact of Coronavirus (Covid-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 231,416,660 cases and 4,741,330 deaths due to coronavirus (COVID-19) were reported till September 26, 2021, across the globe.

The COVID-19 pandemic and lockdown in various countries across the globe has negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. Likewise, COVID-19 pandemic is expected to have a negative impact on the global anal cancer market due to financial challenges faced by hospitals and healthcare facilities during pandemic. For instance, according to an article published by the Elsevier Public Health Emergency Collection journal in November 2020, it is estimated that hospitals and healthcare systems in the U.S. are subjected to a financial impact of US$ 202.6 billion in lost revenue during the pandemic.

Global Anal Cancer Market Restraint

The side effects of chemotherapy drugs used in the treatment of anal cancer are the factors that are expected to hinder growth of the global anal cancer market over the forecast period. For instance, according to an article published by the American cancer Society in November 2017, some of the side effects associated with use of chemotherapy drugs in the treatment of anal cancer include nausea, vomiting, loss of appetite, hair loss, diarrhea, mouth sores, and others.

Key Players

Major players operating in the global anal cancer market include Advaxis, Inc., ORYX GmbH and Co. KG, Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Onconova Therapeutics, BioMimetix JV, LLC, Bayer AG, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., Atara Biotherapeutics Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Sanofi, and Johnson & Johnson Private Limited

Anal cancer is a rare type of cancer in the anal canal. The anal canal is a short tube, about 1-1½ inches long between anal opening and rectum through which stool passes out of the human body. Some of the symptoms associated with anal cancer include anal or rectum bleeding, lump near anus, pain around the anus, itching in the anus, discharge from the anus, changes in bowel habits, and others. Anal cancer can be caused due to a number of risk factors such as human papillomavirus (HPV) infection, having multiple sexual partners, indulging in receptive anal intercourse (anal sex), excessive smoking, medical history of vaginal, cervical or vulvar cancers. Moreover, immune-compromised patients who have a disease or condition which causes weakening of immune system such as organ transplant, human immunodeficiency virus (HIV), and others.

Market Dynamics

The increasing incidence of anal cancer and sexually transmitted diseases, rising research and development activities for the development of novel therapeutics for the treatment of anal cancer, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global anal cancer market over the forecast period.

For instance, according to data provided by the Cancer Research U.K. in 2018, around 1,500 new cases of anal cancer are reported every year in the U.K, i.e. four new anal cancer cases daily. The same source also states that the incidence rate of anal cancer in the U.K. is highest in elderly people of age 90 and above.

Key features of the study:

  • This report provides in-depth analysis of the global anal cancer market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global anal cancer market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Advaxis, Inc., ORYX GmbH and Co. KG, Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Onconova Therapeutics, BioMimetix JV, LLC, Bayer AG, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., Atara Biotherapeutics Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Sanofi, and Johnson & Johnson Private Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global anal cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anal cancer market

Detailed Segmentation:

  • Global Anal Cancer Market, By Drug Type:
    • Fluorouracil
    • Cisplatin
    • Carboplatin
    • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
  • Global Anal Cancer Market, By Cancer Type:
    • Carcinoma In-situ
    • Squamous Cell Carcinoma
    • Melanoma
    • Adenocarcinoma
    • Basal Cell Carcinoma
  • Global Anal Cancer Market, By Treatment Type:
    • Chemotherapy
    • Surgery
    • Radiation Therapy
    • Immunotherapy
  • Global Anal Cancer Market, By Distribution Channel:
    • Hospitals & Clinics
    • Research & Academic Institutes
    • Long-term Care Centers
    • Pharmacies
  • Global Anal Cancer Market, By Region:
    • North America
      • By Drug Type
        • Fluorouracil
        • Cisplatin
        • Carboplatin
        • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • By Cancer Type
        • Carcinoma In-situ
        • Squamous Cell Carcinoma
        • Melanoma
        • Adenocarcinoma
        • Basal Cell Carcinoma
      • By Treatment Type
        • Chemotherapy
        • Surgery
        • Radiation Therapy
        • Immunotherapy
      • By Distribution Channel
        • Hospitals & Clinics
        • Research & Academic Institutes
        • Long-term Care Centers
        • Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Type
        • Fluorouracil
        • Cisplatin
        • Carboplatin
        • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • By Cancer Type
        • Carcinoma In-situ
        • Squamous Cell Carcinoma
        • Melanoma
        • Adenocarcinoma
        • Basal Cell Carcinoma
      • By Treatment Type
        • Chemotherapy
        • Surgery
        • Radiation Therapy
        • Immunotherapy
      • By Distribution Channel
        • Hospitals & Clinics
        • Research & Academic Institutes
        • Long-term Care Centers
        • Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type
        • Fluorouracil
        • Cisplatin
        • Carboplatin
        • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • By Cancer Type
        • Carcinoma In-situ
        • Squamous Cell Carcinoma
        • Melanoma
        • Adenocarcinoma
        • Basal Cell Carcinoma
      • By Treatment Type
        • Chemotherapy
        • Surgery
        • Radiation Therapy
        • Immunotherapy
      • By Distribution Channel
        • Hospitals & Clinics
        • Research & Academic Institutes
        • Long-term Care Centers
        • Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Fluorouracil
        • Cisplatin
        • Carboplatin
        • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • By Cancer Type
        • Carcinoma In-situ
        • Squamous Cell Carcinoma
        • Melanoma
        • Adenocarcinoma
        • Basal Cell Carcinoma
      • By Treatment Type
        • Chemotherapy
        • Surgery
        • Radiation Therapy
        • Immunotherapy
      • By Distribution Channel
        • Hospitals & Clinics
        • Research & Academic Institutes
        • Long-term Care Centers
        • Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type
        • Fluorouracil
        • Cisplatin
        • Carboplatin
        • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • By Cancer Type
        • Carcinoma In-situ
        • Squamous Cell Carcinoma
        • Melanoma
        • Adenocarcinoma
        • Basal Cell Carcinoma
      • By Treatment Type
        • Chemotherapy
        • Surgery
        • Radiation Therapy
        • Immunotherapy
      • By Distribution Channel
        • Hospitals & Clinics
        • Research & Academic Institutes
        • Long-term Care Centers
        • Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Fluorouracil
        • Cisplatin
        • Carboplatin
        • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • By Cancer Type
        • Carcinoma In-situ
        • Squamous Cell Carcinoma
        • Melanoma
        • Adenocarcinoma
        • Basal Cell Carcinoma
      • By Treatment Type
        • Chemotherapy
        • Surgery
        • Radiation Therapy
        • Immunotherapy
      • By Distribution Channel
        • Hospitals & Clinics
        • Research & Academic Institutes
        • Long-term Care Centers
        • Pharmacies
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Advaxis, Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • ORYX GmbH and Co. KG
    • Eli Lilly and Company
    • Merck KGaA
    • Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Onconova Therapeutics
    • BioMimetix JV, LLC
    • Bayer AG
    • Spectrum Pharmaceuticals Inc.
    • Global BioPharma Inc.
    • Amgen Inc.
    • Atara Biotherapeutics Inc.
    • ISA Pharmaceuticals
    • Takeda Pharmaceutical Company Limited
    • Ono Pharmaceutical Co., Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Johnson & Johnson Private Limited

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Cancer Type
      • Market Snippet, By Treatment Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • PEST Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Highlights
    • Reimbursement Scenario
    • Mergers & Acquisitions
  4. Global Anal Cancer Market – Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • Impact on Clinical Trials and Drug Development
    • Government Initiatives
  5. Global Anal Cancer Market, By Drug Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Fluorouracil
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Cisplatin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Carboplatin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  6. Global Anal Cancer Market, By Cancer Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Carcinoma In-situ
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Squamous Cell Carcinoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Melanoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Adenocarcinoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Basal Cell Carcinoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  7. Global Anal Cancer Market, By Treatment Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Chemotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Surgery
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Radiation Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Immunotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  8. Global Anal Cancer Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospitals & Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Research & Academic Institutes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Long-term Care Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  9. Global Anal Cancer Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2028
    • North America
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Cancer Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Cancer Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Cancer Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Cancer Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Cancer Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Cancer Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Region/Country, 2017 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  10. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Advaxis, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ORYX GmbH and Co. KG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck KGaA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • F. Hoffmann-La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Onconova Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • BioMimetix JV, LLC
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Spectrum Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Global BioPharma Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amgen Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Atara Biotherapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ISA Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ono Pharmaceutical Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol-Myers Squibb Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson Private Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  11. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 38 market data tables and 28 figures on "Anal Cancer Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global anal cancer market size is estimated to be valued at US$ 810.4 million in 2021 and is expected to exhibit a CAGR of 6.3% between 2021 and 2028.
Increasing prevalence of sexually transmitted diseases & anal cancer and growing research and development activities by market players for anal cancer treatment are expected to drive the market growth over the forecast period.
Chemotherapy segment is the leading treatment type segment in the market.
North America holds the largest market share in the market.
Major factor hampering growth of the market include side effects of chemotherapy.
Major players operating in the market include Advaxis, Inc., ORYX GmbH and Co. KG, Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Onconova Therapeutics, BioMimetix JV, LLC, Bayer AG, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., Atara Biotherapeutics Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Sanofi, and Johnson & Johnson Private Limited
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.